Rolling The Credits

The Scientist, Nov. 15, 1993, page 12). This is also an immense problem for not-for-profit agencies such as the American Cancer Society. Our credibility largely depends upon reporting back to the American public the progress in cancer research that was made possible by their generous donations. The vast majority of research that we support is of a very fundamental nature and does not make headlines. However, some of it does--some of

Written byJohn Laszlo
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The vast majority of research that we support is of a very fundamental nature and does not make headlines. However, some of it does--some of our grantees win prestigious prizes and receive national, and even worldwide, publicity. When publicity is available, it's a golden opportunity to mention the sponsoring agency or agencies. We generally learn about these press conferences or other potential opportunities after they have passed. Admittedly, the press often ignores the supporting agency, even when it was properly listed at the bottom of the press release. Further, some scientific journals are ruthless in ignoring sponsorship when it comes to press conferences based on articles published in their own journals.

It is terribly important for us to pull together on these matters and to make plans for publicity and proper attribution before the article or the press conference is completed. If we want to encourage public support of research, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies